In the SHR experiment, statistically significant reduction of -14.6 mmHg for Ile-Trp was observed at a lower oral dose (0.1 mg/kg of body weight), as shown in Table 1. Table 1. Effect of Oral Administration of Peptide on Systolic Blood Pressure in SHR
Sample
| Dose (mg/kg)
| Systolic blood pressure (mmHg) b
| Before administration | Time after administration (h)
| 3
| 6
| 9
| Control
|
| 211.4 ± 8.4
| 218.3 ± 6.0
| 209.6 ± 4.8
| 210.1 ± 4.9
| Ile-Trp
| 0.1 | 231.7 ± 5.1
| 228.9 ± 6.4
| 222.6 ± 2.2
| 217.1 ± 4.5* | 1 | 213.3 ± 3.4
| 212.0 ± 3.5
| 209.2 ± 2.5
| 199.5 ± 5.9* | 10 | 224.9 ± 3.3
| 220.7 ± 5.7
| 221.3 ± 5.5
| 223.4 ± 5.7 | Captopril a
| 1
| 238.7 ± 6.9
| 222.2 ± 3.9*
| 221.1 ± 4.0*
| 224.9 ± 4.1* | a Captopril as a positive control. b Systolic blood pressure is shown as mean ± SE, n = 6. * Significantly different from the before administration at p < 0.05 by paired t test. ** Significantly different from the before administration at p < 0.01 by paired t test.
| |